Pharmaceutical firm Cipla on Friday said the US Food and Drug Administration has completed inspection of its Bengaluru-based manufacturing unit with four observations.
The company said it is committed to addressing these observations and will submit its response to the USFDA within the stipulated time.
The inspection of Cipla's API manufacturing facility was carried out between January 20 and 24.
"The United States Food and Drug Administration conducted a cGMP inspection at our API manufacturing facility in Bommasandra, Bangalore, from January 20, 2020, to January 24, 2020. The inspection ended with 4 observations which were procedural in nature and none of which were repeat or related to data integrity," Cipla said in a stock exchange filing.
Disclaimer: No Business Standard Journalist was involved in creation of this content
